Multinational cannabis operator Curaleaf Holdings Inc (TSE: CURA) (OTCMKTS: CURLF) now has the first-ever liquid extract vaporizer certified for prescription to medical cannabis patients in the European Union. It was created through a collaboration with the TILT Holdings Inc (CBOE CA: TILT) (OTCMKTS: TLLTF) (FRA: 0T01) subsidiary Jupiter Research, LLC.
Based in Phoenix, Arizona, Jupiter’s sole focus is vaporizer technology for liquid derivatives like distillate, live resin and full-spectrum oil. TILT is also active in the cannabis flower market.
Building on the achievement of obtaining a medical device certification for the gadget in Europe, Curaleaf International aims to expand distribution throughout Canada, Britain and other nations.
“Wow! Progress in Europe,” commented Will Muecke, Chief Investment and Strategy Officer at the cannabis investment firm Artemis Growth Partners LLC. “Great for patients. Great for the market.”
A magnetic snap-in cartridge is one of the nifty features mentioned in Curaleaf’s press release on the topic.
EU medical device certification is more than a milestone — it’s validation that medical cannabis is becoming a trusted part of global healthcare. Congrats to the @curaleafint team for their success in driving innovation, raising safety standards, and putting patients first.…
— Boris Jordan (@Boris_Jordan) May 12, 2025
Read more: Residents of Turkish town get engulfed with intoxicating cloud of cannabis smoke
First quarter revenue slides by 9%
For the quarter ended Mar. 30, Curaleaf pulled US$310 million in revenue — a slight year-over-year decline. Results were announced last week.
Despite this moderately negative item on the balance sheet, Curaleaf’s international revenue shot up by 74 per cent year-over-year to US$35 million. The new vaporizer device could potentially help the company maintain profitability in global markets outside of the U.S.
Curaleaf also reported an adjusted gross margin of 50 per cent, up 250 basis points or 2.5 per cent. This means that the cannabis operator kept an additional US$0.025 in profit for every dollar of revenue during the 3-month period, in comparison to Q1 of 2024.
In other recent news, CEO and founder Boris Jordan is quite upset about cumbersome industry regulations in New York at the moment. He says Governor Kathy Hochul and state regulators are making acquiring licenses a difficult task and charging local operators a ridiculous amount of money to convert medical dispensaries into adult-use stores.
“New York is directly targeting and hurting our business,” Jordan just told the New York Post.
“It’s very un-American, to be honest. They asked us to invest, and now they want to destroy us.”
Curaleaf is headquartered in New York City.
The medical-grade liquid extract inhaler. Image credit: Jupiter Research, LLC
Read more: Curaleaf forced to fork out US$32M for settlement with Michigan cultivator
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
